Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab chemoradiation with or without sequential cetuximab in locally advanced pancreatic adenocarcinoma
ISRCTN56652283Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Jan 2005
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab and gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Heidelberg University. Primary endpoints: Safety, Feasibility and 1 more. Started Jan 2005; status: completed.
02
Drugs
cetuximabgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN56652283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN56652283.